Argatroban as Anticoagulant in Cardiopulmonary Bypass in an Infant and Attempted Reversal with Recombinant Activated Factor VII
2004; Lippincott Williams & Wilkins; Volume: 100; Issue: 2 Linguagem: Inglês
10.1097/00000542-200402000-00038
ISSN1528-1175
AutoresStephan Malherbe, Ban C. H. Tsui, Kent Stobart, John Koller,
Tópico(s)Venous Thromboembolism Diagnosis and Management
ResumoHEPARIN-INDUCED thrombocytopenia (HIT) is an infrequent complication of heparin therapy. 1 A unique problem arises in patients with HIT who need anticoagulation, especially if urgent cardiac surgery is planned. We report a case of HIT in an infant in which Argatroban (GlaxoSmithKline, Middlesex, UK) was used as anticoagulant during cardiopulmonary bypass (CPB) and the unsuccessful use of recombinant activated factor VII (rF-VIIa) to reverse the anticoagulant effects postoperatively.
Referência(s)